Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
NBIX's Cash to Debt is ranked higher than
98% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. NBIX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NBIX' s Cash to Debt Range Over the Past 10 Years
Min: 1.72  Med: 41.82 Max: No Debt
Current: No Debt
Equity to Asset 0.90
NBIX's Equity to Asset is ranked higher than
93% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NBIX: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
NBIX' s Equity to Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.79 Max: 0.95
Current: 0.9
0.01
0.95
Interest Coverage No Debt
NBIX's Interest Coverage is ranked higher than
96% of the 475 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.69 vs. NBIX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NBIX' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: 9999.99
Current: No Debt
N/A
9999.99
F-Score: 2
Z-Score: 52.91
M-Score: -4.36
WACC vs ROIC
1.50%
-164.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -751.81
NBIX's Operating margin (%) is ranked lower than
95% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.73 vs. NBIX: -751.81 )
Ranked among companies with meaningful Operating margin (%) only.
NBIX' s Operating margin (%) Range Over the Past 10 Years
Min: -17340.03  Med: -476.51 Max: 43.82
Current: -751.81
-17340.03
43.82
Net-margin (%) -713.34
NBIX's Net-margin (%) is ranked lower than
94% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.01 vs. NBIX: -713.34 )
Ranked among companies with meaningful Net-margin (%) only.
NBIX' s Net-margin (%) Range Over the Past 10 Years
Min: -16936.19  Med: -449.84 Max: 48.53
Current: -713.34
-16936.19
48.53
ROE (%) -23.93
NBIX's ROE (%) is ranked lower than
81% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. NBIX: -23.93 )
Ranked among companies with meaningful ROE (%) only.
NBIX' s ROE (%) Range Over the Past 10 Years
Min: -250.63  Med: -35.17 Max: 94.61
Current: -23.93
-250.63
94.61
ROA (%) -21.70
NBIX's ROA (%) is ranked lower than
83% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. NBIX: -21.70 )
Ranked among companies with meaningful ROA (%) only.
NBIX' s ROA (%) Range Over the Past 10 Years
Min: -62.22  Med: -25.54 Max: 26.57
Current: -21.7
-62.22
26.57
ROC (Joel Greenblatt) (%) -1597.01
NBIX's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.13 vs. NBIX: -1597.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NBIX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3172.32  Med: -305.40 Max: 2175.88
Current: -1597.01
-3172.32
2175.88
Revenue Growth (3Y)(%) -33.50
NBIX's Revenue Growth (3Y)(%) is ranked lower than
93% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. NBIX: -33.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NBIX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -12.40 Max: 170.6
Current: -33.5
-100
170.6
» NBIX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

NBIX Guru Trades in Q2 2015

Louis Moore Bacon 55,000 sh (New)
RS Investment Management 711,010 sh (+19.12%)
Paul Tudor Jones Sold Out
Pioneer Investments 144,315 sh (-25.56%)
Steven Cohen 37,700 sh (-83.83%)
» More
Q3 2015

NBIX Guru Trades in Q3 2015

Jim Simons 130,641 sh (New)
RS Investment Management 838,960 sh (+18.00%)
Steven Cohen Sold Out
Pioneer Investments 116,672 sh (-19.15%)
Louis Moore Bacon 35,000 sh (-36.36%)
» More
Q4 2015

NBIX Guru Trades in Q4 2015

Louis Moore Bacon 130,000 sh (+271.43%)
Pioneer Investments 189,473 sh (+62.40%)
Jim Simons Sold Out
RS Investment Management 609,950 sh (-27.30%)
» More
Q1 2016

NBIX Guru Trades in Q1 2016

George Soros 9,400 sh (New)
Pioneer Investments 193,026 sh (+1.88%)
Louis Moore Bacon Sold Out
RS Investment Management 11,090 sh (-98.18%)
» More
» Details

Insider Trades

Latest Guru Trades with NBIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:ENDP, NAS:AKRX, OTCPK:HTSUF, OTCPK:IPSEY, OTCPK:CHSYF, OTCPK:DNPUF, OTCPK:GEDSF, OTCPK:HYPMY, NAS:OPK, OTCPK:STDAF, NAS:HZNP, NYSE:CTLT, OTCPK:SFOSF, OTCPK:INVVY, NAS:MDCO, NYSE:DPLO, NYSE:TARO, OTCPK:SWPIF, OTCPK:SHPHF, NAS:IPXL » details
Traded in other countries:NB3.Germany,
Neurocrine Biosciences Inc discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences Inc, a California corporation was incorporated in January 1992 and was reincorporated in Delaware in May 1996. The Company discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. Its product candidates address pharmaceutical markets internationally, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes and other neurological and endocrine related diseases and disorders. The Company's two late-stage clinical programs are elagolix, a GnRH antagonist in Phase III development for endometriosis and Phase II clinical studies of uterine fibroids that is partnered with AbbVie, and a wholly owned VMAT2 inhibitor for the treatment of movement disorders that is currently in Phase II development. Its clinical development program, elagolix, is a drug candidate for the treatment of endometriosis and uterine fibroids. The Company faces competition from biotechnology and pharmaceutical companies, research institutions, government agencies and academic institutions.

Ratios

vs
industry
vs
history
P/B 10.41
NBIX's P/B is ranked lower than
90% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NBIX: 10.41 )
Ranked among companies with meaningful P/B only.
NBIX' s P/B Range Over the Past 10 Years
Min: 0.9  Med: 5.79 Max: 120
Current: 10.41
0.9
120
P/S 286.82
NBIX's P/S is ranked lower than
98% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. NBIX: 286.82 )
Ranked among companies with meaningful P/S only.
NBIX' s P/S Range Over the Past 10 Years
Min: 3.14  Med: 32.33 Max: 3581.82
Current: 286.82
3.14
3581.82
Current Ratio 17.23
NBIX's Current Ratio is ranked higher than
96% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. NBIX: 17.23 )
Ranked among companies with meaningful Current Ratio only.
NBIX' s Current Ratio Range Over the Past 10 Years
Min: 1.63  Med: 9.53 Max: 26.66
Current: 17.23
1.63
26.66
Quick Ratio 17.23
NBIX's Quick Ratio is ranked higher than
96% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. NBIX: 17.23 )
Ranked among companies with meaningful Quick Ratio only.
NBIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.63  Med: 9.53 Max: 26.66
Current: 17.23
1.63
26.66
Days Sales Outstanding 367.02
NBIX's Days Sales Outstanding is ranked lower than
99% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.90 vs. NBIX: 367.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
NBIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.58  Med: 28.84 Max: 96.77
Current: 367.02
3.58
96.77

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.82
NBIX's Price/Net Cash is ranked higher than
50% of the 253 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.32 vs. NBIX: 12.82 )
Ranked among companies with meaningful Price/Net Cash only.
NBIX' s Price/Net Cash Range Over the Past 10 Years
Min: 2.62  Med: 9.06 Max: 254.67
Current: 12.82
2.62
254.67
Price/Net Current Asset Value 12.10
NBIX's Price/Net Current Asset Value is ranked lower than
69% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. NBIX: 12.10 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NBIX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.79  Med: 6.62 Max: 280
Current: 12.1
1.79
280
Price/Tangible Book 10.40
NBIX's Price/Tangible Book is ranked lower than
85% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.59 vs. NBIX: 10.40 )
Ranked among companies with meaningful Price/Tangible Book only.
NBIX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.11  Med: 4.80 Max: 112.96
Current: 10.4
1.11
112.96
Price/Projected FCF 124.05
NBIX's Price/Projected FCF is ranked lower than
99% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. NBIX: 124.05 )
Ranked among companies with meaningful Price/Projected FCF only.
NBIX' s Price/Projected FCF Range Over the Past 10 Years
Min: 9.15  Med: 25.18 Max: 98.88
Current: 124.05
9.15
98.88
Price/Median PS Value 8.88
NBIX's Price/Median PS Value is ranked lower than
98% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. NBIX: 8.88 )
Ranked among companies with meaningful Price/Median PS Value only.
NBIX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 0.65 Max: 43.53
Current: 8.88
0.12
43.53
Earnings Yield (Greenblatt) (%) -2.87
NBIX's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 844 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. NBIX: -2.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NBIX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.88  Med: 8.60 Max: 3139.3
Current: -2.87
-2.88
3139.3

More Statistics

Revenue (TTM) (Mil) $15.00
EPS (TTM) $ -1.24
Beta-0.01
Short Percentage of Float6.87%
52-Week Range $31.25 - 58.46
Shares Outstanding (Mil)86.66

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 15 94 191
EPS ($) -1.81 -1.34 -0.63
EPS w/o NRI ($) -1.81 -1.34 -0.63
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:NBIX

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Neurocrine Biosciences Aug 31 2015 
Meridian Contrarian Fund Annual Report 2015 Aug 31 2015 
Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 

More From Other Websites
Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : July 20, 2016 Jul 20 2016
Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : July... Jul 19 2016
Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : July... Jul 07 2016
Inside Neurocrine Biosciences’ Focus on Tourette Syndrome Jun 30 2016
Positive Top-Line Data May Help Secure FDA Approval for Valbenazine Jun 30 2016
Inside Neurocrine Biosciences’ Analyst Recommendations in 2016 Jun 29 2016
Coverage initiated on Neurocrine Biosci by H.C. Wainwright Jun 29 2016
Insiders See Huge Upside In These Biotechs Jun 12 2016
Neurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference Jun 02 2016
Neurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference Jun 02 2016
5 stocks to watch Jun 01 2016
Teva’s Huntington Drug Hits A Snag, Lifting Rival Neurocrine May 31 2016
Delayed FDA Decision Sends Sarepta Therapeutics Soaring May 27 2016
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments... May 24 2016
Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors May 20 2016
Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors May 20 2016
ETF’s with exposure to Neurocrine Biosciences, Inc. : May 19, 2016 May 19 2016
NEUROCRINE BIOSCIENCES INC Financials May 12 2016
Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: Q1, 2016 By the Numbers May 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)